Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month (updated)

Zevra Therapeutics

23/09/2024 13:44

(Adds details in paragraph 3, analysts' price estimates in
paragraph 4, background in paragraph 5)
       Sept 23 (Reuters) - Zevra Therapeutics'  ZVRA.O  drug,
Miplyffa, for treating a rare and fatal genetic disorder will
have a wholesale acquisition cost ranging between $40,000 and
$106,000 per month depending on dosage, the company said on a
conference call on Monday.
    The U.S. health regulator on Friday approved the drug making
it the first treatment to get a nod for Neimann-Pick disease
type C (NPC) - a rare genetic condition that affects the nervous
system and other organs.
    The company said the average monthly price is $85,000 per
month based on its expanded access program.
    H.C. Wainwright analysts estimated average net pricing of
the drug to be between $500,000 to $600,000 per year. 
        Miplyffa, in combination with miglustat, was cleared to
treat neurological symptoms associated with NPC in adults and
children 2 years of age and older.

 (Reporting by Kashish Tandon and Sriparna Roy in Bengaluru;
Editing by Shailesh Kuber)
 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))